Effects of morphine on methotrexate disposition in mice

Clinical and Experimental Pharmacology and Physiology

Volumn 31, Issue 4, 2004, Pages 267-270

  Li, Yuai ^a   Looney, Greg A ^a   Hurwitz, Aryeh ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Kidneys; Methotrexate; Mice; Morphine

Indexed keywords

METHOTREXATE; MORPHINE;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; MALE; MOUSE; NONHUMAN; PLASMA CLEARANCE; REDUCTION; URINALYSIS; URINARY EXCRETION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; METHOTREXATE; MICE; MICE, INBRED ICR; MORPHINE;

EID: 1942473733     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2004.03985.x     Document Type: Article

References (43)

1. Calvert AH, Bondy PK, Harrap KR. Some observations on the human pharmacology of methotrexate. Cancer Treat. Rep. 1977; 61: 1647-56.
2. Isacoff WH, Morrison PF, Aroesty J, Willis KL, Block JB, Lincoln TL. Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue. Cancer Treat. Rep. 1977; 61: 1665-74.
3. Nirenberg A, Mosende C, Mehte B, Gisolfi AL, Rosen G. High-dose methotrexate with citrovorum factor rescue: Predictive value of serum methotrexate concentrations and corrective measures to avert toxicity. Cancer Treat. Rep. 1977; 61: 779-83.
4. Breithaupt H, Kuenzlen E. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate. Cancer Treat. Rep. 1982; 66: 1733-41.
5. Chu E, Allegra CJ. Antifolates. In: Chabner BA, Longo DL (eds). Cancer Chemotherapy and Biotherapy, 2nd edn. Lippincott-Raven, Philadelphia. 1996; Ch. 6.
6. Jacobs SA, Stoller RG, Chabner BA, Johns DG. 7-Hydroxymethotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high-dose methotrexate. J. Clin. Invest. 1976; 57: 534-8.
7. Chen M-L, Chiou WL. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate in rabbits after intravenous administration. J. Pharmacokinet. Biopharm. 1983; 11: 499-513.
8. Iven H, Brasch H, Engster J. Pharmacokinetics of methotrexate and 7-hydroxymethotrexate in rabbits. Cancer Chemother. Pharmacol. 1985; 15: 115-20.
9. Azmin MN, Florence AT, Handjani-Vila RM, Stuart JF, Vanlerberghe G, Whittaker JS. The effects of niosomes and polysorbate 80 on the metabolism and excretion of methotrexate in the mouse. J. Microencapsul. 1986; 3: 95-100.
10. Fahrig L, Brasch H, Iven H. Pharmacokinetics of methotrexate (MTX) and 7-hydroxymethotrexate (7-OH-MTX) in rats and evidence for the metabolism of MTX to 7-OH-MTX. Cancer Chemother. Pharmacol. 1989; 23: 156-60.
11. Hurwitz A. Narcotic effects on phenol red disposition in mice. J. Pharmacol. Exp. Ther. 1981; 216: 90-4.
12. Garty M, Hurwitz A. Tolerance to morphine effects on renal disposition of xenobiotics in mice. J. Pharmacol. Exp. Ther. 1986; 239: 346-50.
13. Hurwitz A, Fischer HR. Narcotic effects on hepatic disposition of sulfobromophthalein. J. Pharmacol. Exp. Ther. 1983; 227: 68-72.
14. Hurwitz A, Fischer HR, Innis JD, Ronsse S, Ben-Zvi Z. Opioid effects on hepatic disposition of dyes in mice. J. Pharmacol. Exp. Ther. 1985; 232: 617-23.
15. Ben-Zvi Z, Hurwitz A. Effects of morphine and clonidine on sulphobromophthalein disposition in mice. J. Pharm. Pharmacol. 1986; 238: 481-3.
16. Walker LA, Murphy JC. Effect of denervation on the antinatriuretic response to morphine administration in conscious rats. J. Pharm. Pharmacol. 1986; 237: 799-802.
17. Danesh S, Walker LA. Effect of central administration of morphine on renal function in conscious rats. J. Pharm. Pharmacol. 1986; 244: 640-5.
18. el-Awady ES, Walker LA. Effects of morphine on the renal handling of sodium and lithium in conscious rats. J. Pharm. Pharmacol. 1990; 254: 957-61.
19. Fregoneze JB, Antunes-Rodrigues J. Role of opioid peptides in the renal function of intact and hypophysectomized rats. Physiol. Behav. 1992; 51: 287-92.
20. DiBona GF, Jones SY. Role of endogenous peripheral opioid mechanisms in renal function. J. Am. Soc. Nephrol. 1994; 4: 1792-7.
21. Priano LL, Vatner SF. Morphine effects on cardiac output and regional blood flow distribution in conscious dogs. Anesthesiology 1981; 55: 236-43.
22. Canfell C, Sadee W. Methotrexate and 7-hydroxymethotrexate. Serum level monitoring by high-performance liquid chromatography. Cancer Treat. Rep. 1980; 64: 165-9.
23. Shargel L, Yu ABC. Applied Biopharmaceutics and Pharmacokinetics, 3rd edn. Appleton & Lange, Norwalk. 1993; Ch. 4.
24. Saito H, Masuda S, Inui K. Cloning and functional characterization of a novel rat organic anion transporter mediating basolateral uptake of methotrexate in the kidney. J. Biol. Chem. 1996; 271: 20 719-25.
25. Sun W, Wu RR, van Poelje PD, Erion MD. Isolation of a family of organic anion transporters from human liver and kidney. Biochem. Biophys. Res. Commun. 2001; 283: 417-22.
26. Liegler DG, Henderson ES, Hahn MA, Oliverio VT. The effect of organic acids on renal clearance of methotrexate in man. Clin. Pharmacol. Ther. 1969; 10: 849-57.
27. Aherne GW, Piall E, Marks V, Mould G, White WF. Prolongation and enhancement of serum methotrexate concentrations by probenecid. BMJ 1978; 1: 1097-9.
28. Huang KC, Wenczak BA, Liu YK. Renal tubular transport of methotrexate in the rhesus monkey and dog. Cancer Res. 1979; 39: 4843-8.
29. Williams WM, Chen TS, Huang KC. Effects of penicillin on the renal tubular secretion of methotrexate in the monkey. Cancer Res. 1984; 44: 1913-17.
30. Eaton DL, Klaassen CD. Principles of toxicology. In: Klaassen CD, Amdur MO, Doull J (eds). Cassarett and Doull's Toxicology: The Basic Science of Poisons, 5th edn. McGraw-Hill, New York. 1996; Ch. 2.
31. Borchard RE, Barnes CD, Eltherington LG. Drug Dosage in Laboratory Animals: A Handbook, 3rd edn. Telford Press, Caldwell. 1990.
32. Lowenstein E, Hallowell P, Levine FH, Daggett WM, Austen WG, Laver MB. Cardiovascular response to large doses of intravenous morphine in man. N. Engl. J. Med. 1969; 281: 1389-93.
33. Cherny NI, Portenoy RK. Cancer pain management: Current strategy. Cancer 1993; 72: 3393-415.
34. Soliman T. A Manual of Pharmacology, 8th edn. WB Saunders, Philadelphia. 1957.
35. Gosselin RE, Hodge HC, Smith RP, Gleason MK. Clinical Toxicology of Commercial Products, 4th edn. Williams & Wilkins, Baltimore. 1976.
36. Dorr RT, Von Hoff DD. Cancer Chemotherapy Handbook, 2nd edn. Appleton & Lange, Norwalk. 1994.
37. Aqueterra I, Aldaz A, Giráldez J, Sierrasesúmaga L. Pharmacodynamics of high-dose methotrexate in pediatric patients. Ann. Pharmacother. 2002; 36: 1344-50.
38. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother. Rep. 1966; 5: 219-44.
39. Scheufler E. Evidence for nonlinear pharmacokinetics of methotrexate in the rat. Pharmacology 1982; 25: 51-6.
40. Lawrence JR, Steele WH, Stuart JFB, McNeill CA, McVie JG, Whiting B. Dose dependent methotrexate elimination following bolus intravenous administration. Eur. J. Clin. Pharmacol. 1980; 17: 371-4.
41. Li Y, Looney GA, Kimler BF, Hurwitz A. Opiate effects on 5-fluorouracil disposition in mice. Cancer Chemother. Pharmacol. 1997; 39: 273-7.
42. Innis JD, Meyer M, Hurwitz A. A novel acute toxicity resulting from the administration of morphine and adriamycin to mice. Toxicol. Appl. Pharmacol. 1987; 90: 445-53.
43. Hansten PD, Horn JR. Drug Interactions: Analysis and Management. Facts and Comparisons, St Louis. 2001.